1. Home
  2. KSS vs PHVS Comparison

KSS vs PHVS Comparison

Compare KSS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$17.04

Market Cap

2.0B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$33.07

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
PHVS
Founded
1962
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
KSS
PHVS
Price
$17.04
$33.07
Analyst Decision
Sell
Buy
Analyst Count
15
11
Target Price
$15.31
$41.82
AVG Volume (30 Days)
3.8M
1.0M
Earning Date
05-28-2026
05-12-2026
Dividend Yield
3.58%
N/A
EPS Growth
142.86
N/A
EPS
1.18
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.21
N/A
P/E Ratio
$15.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.38
$20.65
52 Week High
$25.22
$43.25

Technical Indicators

Market Signals
Indicator
KSS
PHVS
Relative Strength Index (RSI) 55.14 43.18
Support Level $18.23 $32.77
Resistance Level $20.00 $36.80
Average True Range (ATR) 0.74 1.99
MACD 0.08 -0.33
Stochastic Oscillator 65.35 5.01

Price Performance

Historical Comparison
KSS
PHVS

About KSS Kohl's Corporation

Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: